In today’s episode I covered the different types of drug interactions, followed by features of clinical drug evaluation studies recommended in the guidance. Then I will review recommendations for both stand-alone clinical drug interaction studies, as well as nested drug interaction studies. I’ll finish with recommended approaches for interpreting drug interaction study results and expressing that information in drug labeling. Links discussed in the show: Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis by Delara et al. FDA guidance on clinical drug interactions FDA guidance on in vitro drug interactions FDA guidance on therapeutic protein drug interactions EMA guideline on drug interactions You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related